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ABSTRACT 
Introduction: Although prostate-specific antigen (PSA) is the most valuable tumor marker for the 
diagnosis and management of prostate carcinoma, it is widely accepted that PSA is not prostate 
specific.  
Objectives: The aim of this study is to address the possibility of using the PSA as marker for the 
sex assignment in different categories and relevance of this test in women problems. 
Method: We have evaluated the measurement of serum total PSA for differentiation between 
Sudanese women with advanced breast cancer (n= 10), and those are lactating (n=10), pregnant 
(n=10) compared with 20 healthy women as control group. 
Serum total PSA (TPSA) was measured using immuno-radiometric assay (IRMA).  
Results: In this study the mean age was significantly higher advanced breast cancer groups 
compared with lactating group (P<0.01). The mean serum PSA levels in the healthy control women 
examined (n=20) was 0.72 ± 0.55 vs. 1.18 ± 0.92, 1.42 ± 2.43 and 0.51 ± 0.13 ng/ml in serum from 
advanced breast cancer (n=10), pregnant (n=10) and lactating women (n=10) respectively. A 
significant high level of total PSA in serum of advanced breast cancer compared with the normal 
group (P< 0.05). 
Conclusion: These results indicated the possible use of total PSA to distinguish between healthy 
women and/or women with advanced breast cancer. 
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rostate-specific antigen (PSA) has been 
biochemically and molecularly 
characterized as a 33-kDa androgen 
dependent glycoprotein related to the 
kallikrein family of serine proteases, with 
chymotrypsin and kallikrein-like enzymatic 
activity1, 2.  
Prostate specific antigen (PSA) is well-
established tumor marker for the diagnosis 
and management of prostate cancer. With the 
advent of more sensitive methodologies for 
PSA detection  and  measurement  came  the  
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finding that PSA is not prostate specific, but 
is present in female tissues, predominantly the 
breast and its secretions3. 
Since the initial discovery of PSA in females, 
numerous normal and pathological tissues and 
bodily fluids have been reported to have PSA 
immunoreactivity. PSA is detectable in 
healthy breast tissue4, 5, and is present in 
breast tumors6, 7 and breast cystic disease4, 8, 9. 
Various breast secretions contain PSA, 
including nipple aspirate fluid (NAF)10, 11, the 
milk of lactating women12, and breast cystic 
fluid8, 13. Endometrial tissue produces PSA14, 
as do ovarian tumors15, and PSA is present in 
amniotic fluid and maternal serum during 
pregnancy12, 16- 18. Low levels of circulating 
PSA are detectable in female sera19.  
We have previously evaluated the usage of 
F/T PSA and PAP (prostate acid phosphatase) 
as tumor markers in Sudanese patients20. 
However, measurement of PSA in pregnant 
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and advanced breast cancer women as well as 
in normal females was not done.  
The aim of this study is to address the 
possibility of using the PSA as marker for the 
sex assignment in different categories and 
relevance of this test in women problems. 
 
MATERIALS AND METHODS 
In this prospective study, we examined 10 
patients with advanced breast cancer at the 
Institute of Nuclear Medicine, Molecular 
Biology, and Oncology (INMO). Those 
patients were histologically and 
ultrasonography confirmed with breast cancer 
(BC) without any other malignancy. 
Advanced breast cancer patients with a 
history of active heart disease, organ failure, 
diabetes, acute infections in the previous 4 
weeks were excluded from this study. Blood 
was also drawn from pregnant women (n=10), 
and lactating women (n=10) referred to the 
department of Obstetrics and Gynecology at 
Medani Maternity Hospital. Samples were 
obtained from the excess blood taken for their 
relevant conditions.   
The control group included 20 healthy women 
between the age 10 and 75 years who revealed 
no breast cancer pathology and not pregnant 
or lactating as well. The age, age at menarche, 
parity and body max index were recorded for 
each participant. 
All the study subjects gave informed consent 
to the study, which was approved by the 
Institutional Medical Ethics Review Board of 
the University of Gezira. 
Blood samples were collected in 5 ml sterile 
vacutainers containing ethylene diamine tetra 
acetic acid (EDTA). After blood clotting, the 
samples were centrifuged within 20 minutes 
after collection at 500 x g for 10 min, and sera 
were stored at -20 ºC until assay.  
The free and total prostate-specific antigens 
were assessed using an immunoradiometric 
assay (Skybio, London, UK) based on two 
anti-PSA antibodies: 125I- labeled and other 
one as solid phase. All tubes were counted for 
100 seconds on multi-well gamma counter. 
The standard curve was drawn as (% 
bound/total counts) vs. log free PSA 
concentration. Quality control and samples 
were determined by interpolation. The mean, 
standard deviation and percentiles were 
calculated and the differences between means 
were analyzed using student unpaired t-test. 
All data were analyzed by using the SPSS 
computer program and the P<0.05 was 
considered to be statistically significant.   
 
Results 
Ten patients with advanced breast cancer 
were enrolled in this prospective study. Table 
1 presents the distribution of the mean ages± 
SD of different groups.  
There was high significant difference 
(P<0.01) in the age between lactating and 
advanced breast cancer groups. 
The lowest mean concentration of total PSA 
in serum samples was reported in the lactating 
group, and the highest one was in the 
pregnant group despite the insignificant 
difference between them.  
Discussion: 
Earlier reports has suggested that 
immunoreactive prostate specific antigen (IR-
PSA) positivity of breast tumors is a favorable 
prognostic indicator for women with breast 
cancer21, 22 and that high serum levels of PSA 
in women might represent a valuable 
diagnostic marker in breast cancer23, 24. In this 
study we are trying to investigate for the 
presence of PSA as a marker in Sudanese 
women with different categories (lactating, 
pregnant and advanced breast cancer) and to 
see whether this marker could be favourable 
prognostic indicator. Our previous study 
indicated the usefulness of measuring PSA in 
the differential diagnosis of prostate 
carcinoma (PCa) and benign prostatic 
hyperplasia (BPH) in Sudanese patients with 
prostate enlargement25. 
We measured the total PSA in serum- not in 
milk- of lactating women in order to compare 
it with that in serum of other study subjects, 
because there was reported considerable 
variation in the concentration of PSA which 
was mostly present as free PSA25. 
Furthermore the major difficulties encounter 
the detection of free PSA in serum led us 
preferentially to use total PSA instead of free 
PSA.
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Table 1: distribution of the patients according to age of the lactating, pregnant, advanced breast 
cancer and healthy women as control group.   
 
Clinical data Lactating group  
(Mean ± SD) 
Pregnant group  
(Mean ± SD) 
Adv. Breast cancer 
group (Mean ± SD) 
Control 
 (Mean ± SD) 
P-
value 
















Table 2:  
Means, medians and ranges of total prostate specific antigen in the serum of lactating, pregnant and 
advanced breast cancer women compared with healthy women as control group.   
Groups Total PSA (ng/ml) 
 
 (Mean ± SD) Median Range 
Lactating                 (n=10) 0.51 ± 0.13 0.50 0.3 – 0.8 
Pregnant                  (n=10) 1.42 ± 2.43 0.50 0.1 – 8.2 
Adv. Breast cancer (n=10) 1.18 ± 0.92* 1.30 0.1 – 2.6 
Control                    (n=20) 0.72 ± 0.55* 0.60 0.1 - 1.9 
In this study we found a significant deference 
in the age between advanced breast cancer 
and lactating females and that was 
accompanied with an increase or decrease in 
the total PSA. This notion supported the data 
that total PSA concentration decreases with 
women’s age23. This also indicated the 
possible association between the high levels 
of total PSA and the progression of breast 
malignancy. Supportive evidence reported the 
remarkable presence of PSA in female’s 
breast tumors that are positive to steroid 
hormones receptor. It was also found to be 
associated in patients with early stage disease 
and age less than 50 years26, 27. Romppanen et 
al.28 reported an association between the age 
and the decrease of total PSA in normal 
control and breast cancer patients which was 
in agreement with our results.  
We found high significant level of total PSA 
in women with advanced breast cancer 
compared with the normal subjects. This 
result was in agreement with others who 
reported high levels of serum total PSA in 
both benign and malignant breast cancer23, 29. 
Recent study has proposed PSA as a new 
marker for the assessment of benign breast 
tumors29.   
It is important to note that the number in this 
study is too small to reach firm conclusions. 
Nevertheless, our finding of serum total PSA 
in breast tumor, lactating and pregnant 
women together with the data presented by 
others28, 30 suggest that PSA can no longer be 
regarded as specific prostatic marker. 
However, it can be used to distinguish 
between healthy women and/or women with 
advanced breast cancer. 
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Further studies with large sample size are 
required to prove our finding. 
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